Ameliorative effects of dietary beta-conglycinin in metabolic syndrome

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K00834
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Eating habits
• Research Institution: University of Nagasaki
• Principal Investigator: Koba Kazunori 長崎県立大学, 看護栄養学部, 教授 (30290638)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: β-コングリシニン / 脂肪組織重量 / 肝臓トリグリセリド濃度 / 血圧 / 血糖値 / ラット / マウス / メタボリックシンドローム

Outline of Final Research Achievements

We examined how dietary β-conglycinin, one of the major components of soy protein affected metabolic syndrome factors in disease animal models. As a result, dietary β-conglycinin lowered visceral adipose tissue weights and liver triglyceride concentration in Otsuka Long Evans Tokushima Fatty (OLETF) rats (an animal model of obesity). Dietary β-conglycinin suppressed both systolic and diastolic blood pressures in spontaneously hypertensive rats (SHR/Izm). Also, Dietary β-conglycinin ameliorated insulin sensitivity in KK-Ay mice (a mouse model of type II diabetes mellitus). These effects were also observed in SHR/NDmcr-cp, which was a metabolic syndrome rat model. The results suggested that β-conglycinin could modulate not only lipid metabolism, but also glucose metabolism and blood pressure in rodents, and then β-conglycinin has potential to prevent metabolic syndrome.

Free Research Field

食品栄養学